Infliximab-induced eruptive sebaceous hyperplasia in patient treated for ulcerative Colitis: first reported case

Abstract

Multiple eruptive sebaceous hyperplasia (SH) is a well-known skin side-effect often occurring during cyclosporine administration, especially in kidney transplanted patients. On physiopatogenic basis, SH may be directly related to the cyclosporine induced immunosuppression, driving to dysplastic epithelial proliferation or may be an idiosyncratic consequence of cyclosporine effect like hypertrichosis. Nowadays, treatment with TNF alpha inhibitors is a cornerstone in a multitude of inflammatory and immune-mediated diseases like psoriasis hidradenitis suppurativa, arthritis, and inflammatory bowel diseases. TNF alpha inhibitors exert their activity on innate and adaptive immune system through immunomodulatory rather than immunosuppressive action, thus common side effects occurring during treatment with cyclosporine or another immunosuppressive agent are rarely described. Here, we report the first case of multiple eruptive sebaceous hyperplasia of the face, in a patient receiving infliximab for ulcerative colitis.